Chronic pelvic pain syndrome (CPPS), defined as nonspecific, poorly localized pelvic pain without an identifiable pathology for at least 3 of the preceding 6 months, is classified as category III of prostatitis by the National Institutes of Health (NIH; [@bibr14-1557988317736585]). It is a common disorder in men, with the average prevalence at different ages being reported as approximately 10% ([@bibr26-1557988317736585]). Global statistics identified that the epidemiology ranges from 2.2 to 9.7%, with a mean prevalence of 8.2% ([@bibr13-1557988317736585]). CPPS-like symptoms greatly affect urinary symptoms, quality of life (QoL), and even sexual function ([@bibr17-1557988317736585]; [@bibr36-1557988317736585]). Although the pathophysiology of CPPS is usually multifactorial, the most common etiology is physiological disorders ([@bibr7-1557988317736585]; [@bibr21-1557988317736585]). By covering major physiological etiologies, directed 3-As therapy (antibiotics, alpha blockers, and anti-inflammatories), rather than monotherapy, is often used as a first-line treatment for patients with CPPS because of its convenience and good efficacy ([@bibr2-1557988317736585]; [@bibr34-1557988317736585]). Up to 46% of patients with CPPS do not respond sufficiently to the traditional 3-As therapy ([@bibr34-1557988317736585]).

Traditional second-line treatments, including phytotherapy, hormone agents, neuromodulators, physical therapies, psychological treatment, or lifestyle modifications could serve as salvage therapies for patients with refractory CPPS ([@bibr12-1557988317736585]; [@bibr21-1557988317736585]). Other invasive procedures, such as transcutaneous electrical nerve stimulation, intraprostatic injection, and even radical prostatectomy, have been discussed ([@bibr4-1557988317736585]; [@bibr31-1557988317736585]). Although these treatments are sometimes effective, they have many disadvantages, such as invasiveness, inconvenience, or side effects, and most patients may withdraw from them. Since 2009, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) demonstrated the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network to approach CPPS in a systemic manner. It described a new and novel integrated approach to define patient phenotypes, identify clinically relevant subgroups, and better understand treated natural history and pathophysiology ([@bibr5-1557988317736585]). Shoskes et al. reported that a more detailed description of clinical phenotyping with seven domains, including urinary, psychosocial, organ specific, infection, neurologic/systemic, tenderness, and sexual dysfunction (UPOINTS), is recommended to manage the poly-symptomatic presentation of patients with CPPS ([@bibr21-1557988317736585]; [@bibr32-1557988317736585]). After a phenotype-directed approach, arranging a safe, convenient, and noninvasive therapy that can cover the remaining domains (such as organ specific, neurologic, sexual dysfunction, and tenderness) of UPOINTS to maximize the treatment effects in patients with refractory CPPS would be reasonable.

Low-intensity extracorporeal shock wave therapy (LI-ESWT), a noninvasive therapy, has been applied recently in the treatment of CPPS ([@bibr24-1557988317736585]) because it can induce neovascularization and anti-inflammation, nerve impulse interruption, reduce passive muscle tone, influence neuroplasticity of the pain memory, and is well applied in musculoskeletal disorders, peripheral neuropathy, and inflammatory diseases ([@bibr11-1557988317736585]; [@bibr22-1557988317736585]; [@bibr24-1557988317736585]; [@bibr30-1557988317736585]). Zimmermann et al. demonstrated that extracorporeal shock waves at a low-energy density could enhance improvement of pain, urination, erectile function, and QoL ([@bibr44-1557988317736585]). Although most of the published results identified that LI-ESWT can be a useful treatment for patients with CPPS, particularly those who are still responders to 3-As therapy ([@bibr24-1557988317736585]; [@bibr27-1557988317736585]; [@bibr44-1557988317736585]), few studies have evaluated the role of LI-ESWT in patients with refractory CPPS who were nonresponders to 3-As therapy. The aim of the current study is to evaluate whether a combined phenotype-directed approach and LI-ESWT can improve clinical symptoms and QoL in Taiwanese patients refractory to 3-As therapy.

Materials and Methods {#section1-1557988317736585}
=====================

This was an open-label, single-arm prospective study. Patients who were unable to achieve clinical improvement after receiving full dosages of the 3-As therapy between January 2016 and December 2016 were enrolled from Kaohsiung Municipal Ta-Tung Hospital and Hsiao-Kang Hospital, in southwestern Taiwan. Eligible subjects were more than 18 years old and in a stable mental status. All patients had received at least a 6-week trial of 3-As therapy, including fluoroquinolone (500 mg once daily), alpha-blocker (recommend dose once daily), and acetaminophen/nonsteroidal anti-inflammatory drug (NSAID; recommend dose twice or three times daily). These patients did not have more than a 6-point decrease in the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total score after taking the full course and maximal dosage of the 3-As therapy for at least 3 of the preceding 6 months ([@bibr34-1557988317736585]). If unrecognized hypogonadism with serum total testosterone levels \<350 ng/dL was noted during initial screening, a testosterone replacement therapy (TRT) trial of at least 3 months was performed first to restore testosterone levels to a normal range ([@bibr3-1557988317736585]; [@bibr37-1557988317736585]). If prostate-specific antigen (PSA) levels \>4 ng/mL were noted during initial screening, prostate biopsy was performed first to exclude potential malignancy. Before the LI-ESWT treatment period, all patients received phenotype-directed approach by a urologist. Subjects were excluded if they had significant coagulopathy, perineal anatomical abnormalities, neurological abnormalities, unstable psychiatric disorders, uncorrected hormone abnormalities, clinically significant medical diseases, and history of extensive pelvic surgery or irradiation. Subjects with unstable psychosocial problems were excluded, and specialist counseling was performed simultaneously, unless their condition had improved. Only those subjects who still failed to respond to 3-As therapy after their clinical phenotypes were reevaluated and corrected were enrolled. The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital. Each participant provided signed informed consent.

Initial Screening {#section2-1557988317736585}
-----------------

All participants were assessed using a structured questionnaire to collect their demographic information and detailed medical, surgical, psychiatric, and sexual history. The well-known risk factors for CPPS, including genitourinary tract infection, pelvic organ surgery/trauma, psychological disorder, diabetes, hypertension, hyperlipidemia, cardiovascular disease, peripheral or central neuropathy, sleep disorder, hypogonadism, cigarette smoking, alcohol drinking, betel nut chewing, sexual activity, and exercise habits were completely reviewed ([@bibr9-1557988317736585]; [@bibr28-1557988317736585]; [@bibr41-1557988317736585]). The subjects were classified as alcohol drinkers, cigarette smokers, or betel nut chewers if they had consumed any alcoholic beverage ≥1 time per week, had smoked ≥10 cigarettes per week, or had chewed ≥10 betel nuts per week for at least 6 months. Current users were those who were still using any of these substances within 1 year before the interview ([@bibr20-1557988317736585]; [@bibr41-1557988317736585]). The subjects were classified as those who had regular sexual activity or exercise habits if they had sexual activity at least two times per week or exercised 30 to 60 min per day, 2 to 3 times per week, respectively, for at least the past 6 months ([@bibr9-1557988317736585]; [@bibr15-1557988317736585]). In addition to a detailed physical examination, 20-mL blood samples were drawn from all participants between 8:00 and 11:00 AM after overnight fasting \>8 hr, for analyses of serum glucose, lipid panels, routine biochemical profiles, PSA, and total testosterone levels. Baseline evaluation of each participant was assessed using detailed questionnaires, including NIH-CPSI score, visual analog scale (VAS) score, International Prostate Symptom Score (IPSS), five-item version of the International Index of Erectile Function (IIEF-5), erection hardness score (EHS), and self-reported intravaginal ejaculation latency time (IELT).

Treatment Protocol {#section3-1557988317736585}
------------------

All participants underwent LI-ESWT (Duolith SD1 T-TOP, Storz, Switzerland) once weekly for 4 weeks in an outpatient setting without local or systemic anesthesia. At each treatment session, LI-ESWT was applied on the perineum at six different anatomical sites (500 shocks per site with a total of 3,000 shocks) with an energy setting of 0.25 mJ/mm^2^ at a frequency of 240 shocks/min. Because the penetration depth of LI-ESWT is adequate for covering the pelvic organs, the application site at the perineum differed for achievement of maximal treatment. During the LI-ESWT treatment period, patients added or remained on their regular medicine dosing schedules, including alpha-blockers and anti-inflammatories, in subjects with special domains. Because all patients had received full-dose antibiotics before enrolling into this study, antibiotics were not used. Dose tapering of the anti-inflammatories and alpha-blockers was allowed and dependent on the clinical condition.

Outcome Measures of LI-ESWT {#section4-1557988317736585}
---------------------------

Clinical symptoms of the participants were reassessed using NIH-CPSI score, VAS score, IIEF-5, and IPSS at 1, 4, and 12 weeks after a complete course of LI-ESWT. The main outcome measure for efficacy of LI-ESWT was the NIH-CPSI total score. Treatment success was defined as a 6-point decrease or greater in the NIH-CPSI total score, which provided a valid outcome measure for response to therapy ([@bibr19-1557988317736585]). During treatment, any adverse effect associated with LI-ESWT was recorded. The protocol and its application are depicted in [Figure 1](#fig1-1557988317736585){ref-type="fig"}.

![Flow chart of sample selection and treatment protocol.](10.1177_1557988317736585-fig1){#fig1-1557988317736585}

Statistical Analysis {#section5-1557988317736585}
--------------------

Quantitative data were represented as means ± standard deviations (*SD*), and categorical data were represented as numbers (*n*) and percentages. To quantify the difference between subjects with and without response to LI-ESWT, categorized variables were compared using the chi-square test and Fisher's exact test, whereas continuous variables were compared using the Student's *t*-test. For all statistical analyses, *p* \< .05 was considered statistically significant. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

Results {#section6-1557988317736585}
=======

A total of 33 patients with a mean age of 46.55 ± 13.15 years and waist circumference of 86.12 ± 7.49 cm were enrolled. The mean history of CPPS was 43.14 months (range: 6--360 months), with 17 patients (51.5%) CPPS IIIa and 16 patients (48.5%) CPPS IIIb. Because patients could have more than one comorbidity, all comorbidities are reported in [Table 1](#table1-1557988317736585){ref-type="table"}. More than half of the patients had been diagnosed with sleep disorder (63.6%) and a history of genitourinary tract infection (60.6%). The prevalence of current smoking and regular exercise was 39.4 and 45.5%, respectively. The mean serum PSA was 1.59 ± 1.57 ng/mL. Of the 33 patients, 2 (6.1%) had serum PSA levels \>4 ng/mL. With regard to medical treatment with an insufficient response before LI-ESWT, our patients failed to respond to a maximal dosage of antibiotics, anti-inflammatory drugs, and alpha-blockers, in a mean trial of 3.76, 9.59, and 23.7 months, respectively ([Table 1](#table1-1557988317736585){ref-type="table"}).

###### 

Baseline Characteristics of Study Population (*N* = 33).

![](10.1177_1557988317736585-table1)

  Parameter                            *N* (%)                       Mean (±*SD*)      Range
  ------------------------------------ ----------------------------- ----------------- ------------------
  Age (years)                                                        46.55 (13.15)     (23--72)
  BMI (kg/m^2^)                                                      24.34 (2.79)      (18.72--32.22)
  Waistline (cm)                                                     86.12 (7.49)      (73--107)
  CPPS period (months)                                               43.14 (62.82)     (6--360)
                                       CPPS category                                   
   CPPS IIIa                           17 (51.5)                                       
   CPPS IIIb                           16 (48.5)                                       
                                       Comorbidities and lifestyle                     
   Genitourinary tract infection       20 (60.60)                                      
   Pelvic organ surgery or trauma      6 (18.20)                                       
   Psychological disorder              4 (12.10)                                       
   Diabetes mellitus                   2 (6.10)                                        
   Hypertension                        6 (18.20)                                       
   Hyperlipidemia                      9 (27.30)                                       
   Cardiovascular disease              2 (6.10)                                        
   Peripheral or central neuropathy    4 (12.10)                                       
   Sleep disorder                      21 (63.60)                                      
   Hypogonadism                        6 (18.20)                                       
   Current smoking                     13 (39.40)                                      
   Current alcohol drinking            12 (36.40)                                      
   Current betel nut chewing           3 (9.10)                                        
   Regular sexual activity             24 (72.70)                                      
   Regular exercise habits             15 (45.50)                                      
                                       Laboratory data                                 
   Total testosterone (ng/dL)                                        521.02 (170.45)   (220.80--863.30)
   Prostate-specific antigen (ng/mL)                                 1.59 (1.57)       (0.3--7.1)
   Creatinine (mg/dL)                                                0.92 (0.15)       (0.6--1.2)
   Alanine aminotransferase (mg/dL)                                  25.97 (9.09)      (15--56)
   Fasting sugar (mg/dL)                                             102.18 (24.07)    (78--214)
   Triglycerides (mg/dL)                                             120.12 (47.08)    (53--539)
   Total cholesterol (mg/dL)                                         178.03 (35.34)    (97--264)
   High-density lipoprotein (mg/dL)                                  45.56 (13.65)     (30.8--107.0)
   Low-density lipoprotein (mg/dL)                                   107.07 (26.89)    (36.10--168.00)
                                       History of medicine                             
   Antibiotics(months)                                               3.76 (3.35)       (2--15)
   Anti-inflammatory                                                 9.59 (9.05)       (2--45)
   Alpha-blocker                                                     23.7 (44.08)      (2--240)

*Note.* CPPS = chronic pelvic pain syndrome; *SD* = standard deviation.

Changes in clinical symptoms at the 1-week, 1-month, and 3-month follow-up after 4 weeks of LI-ESWT are reported in [Table 2](#table2-1557988317736585){ref-type="table"}. The mean value of the NIH-CPSI total score decreased from 28.03 ± 6.18 to 18.97 ± 8.35 and 15.06 ± 7.67, with a difference of 9.06 and 12.97 (*p* \< .001) at the 1-month and 3-month follow-up period, respectively. Of 33 patients, 27 (81.82%) had a successful response (6-point decrease or greater in the NIH-CPSI total score) to LI-ESWT, with a decrease of 3.29 and 5.97 in VAS score and total IPSS, respectively, at the 3-month follow-up period. The mean value of the IIEF-5 also increased from 17.52 ± 4.71 to 19.42 ± 4.12 points, with a difference of 1.9 (*p* = .002) at the 3-month follow-up. No difference was identified in IELT after LI-ESWT (*p* = .177). The improvement of pain, urination, and erectile function could be noted at 1-week follow-up and persistent at the 1-month and 3-month follow-up ([Figure 2](#fig2-1557988317736585){ref-type="fig"}). No adverse effect associated with LI-ESWT, such as hematuria, hemospermia, perineal pain, or ecchymosis, was seen in any of the patients.

###### 

Change of Clinical Symptoms After LI-ESWT (*n* = 33).

![](10.1177_1557988317736585-table2)

                                    Baseline   After LI-ESWT                                                         
  --------------------------------- ---------- --------------- ------- --------- ------- --------- ------- --------- --------
  NIH-CPSI, Mean (±*SD*)            \-         \-              \-      \-                                            
   Total score                      28.03      (6.18)          18.48   (6.97)    18.97   (8.35)    15.06   (7.67)    \<.001
   Pain subscales                   12.85      (3.17)          7       (3.67)    7.79    (4.72)    5.64    (4.21)    \<.001
   Urinary subscales                5.85       (2.40)          4.55    (2.55)    3.94    (2.37)    3.67    (2.30)    \<.001
   QoL subscales                    9.33       (2.10)          6.94    (2.59)    7.24    (2.81)    5.76    (2.65)    \<.001
  CPSI decline ≥6, *n* (%)          NA                         25      (75.80)   25      (75.80)   27      (81.82)   
  VAS, mean (±*SD*)                 5.56       (1.64)          2.79    (1.98)    3.18    (2.40)    2.27    (2.18)    \<.001
  IPSS, mean (±*SD*)                                                                                                 
   Total score                      14.97      (8.88)          11.55   (7.19)    9.79    (7.52)    9       (6.59)    \<.001
   Irritative score                 6.82       (3.17)          5.33    (2.71)    4.55    (2.99)    4.15    (2.86)    \<.001
   Obstructive score                8.15       (6.11)          6.21    (5.08)    5.24    (4.94)    4.85    (3.99)    \<.001
  IIEF-5, mean (±*SD*)              17.52      (4.71)          19.03   (4.22)    18.97   (4.47)    19.42   (4.12)    .002
  EHS, mean (±*SD*)                 3.18       (0.92)          3.45    (0.79)    3.45    (0.71)    3.48    (0.71)    .047
  IELT (min), mean (±*SD*)          4.39       (2.84)          4.53    (2.87)    3.89    (2.64)    4.09    (2.85)    .177
  Medication tapering, *n* (%)      NA                         24      (72.70)   28      (84.80)   29      (87.90)   
  Current painkiller use, *n* (%)   NA                         23      (69.70)   18      (54.50)   12      (36.40)   

*Note.* EHS = erection hardness score; IELT = intravaginal ejaculation latency time; IIEF-5 = five-item version of the International Index of Erectile Function; IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shockwave therapy; NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index, QoL = quality of life; *SD* = standard deviation; VAS = visual analog scale; W = week.

![The improvement of pain, urination, and erectile function during 1-week, 1-month, and 3-month follow-up.](10.1177_1557988317736585-fig2){#fig2-1557988317736585}

Clinical characteristics and laboratory data of subjects with and without a response to LI-ESWT at the 3-month follow-up period revealed no significant difference in age, body mass index (BMI), CPPS period and category, common comorbidities, lifestyle, current cigarette smoking and alcohol drinking, or laboratory data ([Table 3](#table3-1557988317736585){ref-type="table"}). However, subjects with higher waist circumference at baseline had a significantly low response rate to LI-ESWT (*p* = .022).

###### 

Comparison of Clinical Characteristics and Laboratory Data Between Subjects With and Without Response to LI-ESWT.

![](10.1177_1557988317736585-table3)

  ---------------------------------------------------------------------------------------------------------------
  Parameter                                    Subjects without response\   Subjects with response\   *p* value
                                               (*N* = 6)                    (*N* = 27)                
  -------------------------------------------- ---------------------------- ------------------------- -----------
  Age (years), mean (±*SD*)                    42.67 (16.12)                47.41 (12.58)             .433

  BMI (kg/m^2^), mean (±*SD*)                  25.85 (3.97)                 24.00 (2.44)              .147

  Waistline (cm), mean (±*SD*)                 92.33 (10.30)                84.74 (6.13)              .022

  CPSS period (months), mean (±*SD*)           31.67 (26.65)                45.69 (68.43)             .629

  CPPS category, *n* (%)                                                                              

   CPPS IIIa                                   4 (66.70)                    13 (48.10)                .656

   CPPS IIIb                                   2 (33.30)                    14 (51.90)                

  Comorbidities, *n* (%)                                                                              

   Genitourinary tract infection               4 (66.70)                    16 (59.30)                \>.999

   Pelvic organ surgery or trauma              2 (33.30)                    4 (14.80)                 .295

   Psychological disorder                      1 (16.70)                    3 (11.10)                 \>.999

   Diabetes mellitus                           1 (16.70)                    1 (3.70)                  .335

   Hypertension                                1 (16.70)                    5 (18.50)                 \>.999

   Hyperlipidemia                              2 (33.30)                    7 (25.90)                 \>.999

   Cardiovascular disease                      1 (16.70)                    1 (3.70)                  .335

   Peripheral or central neuropathy            0 (0.00)                     4 (14.80)                 NA

   Hypogonadism                                2 (33.30)                    4 (14.80)                 .295

   Current smoking                             2 (33.30)                    11 (40.70)                \>.999

   Current alcohol drinking                    1 (16.70)                    11 (40.70)                .379

   Current betel nut chewing                   1 (16.70)                    2 (7.40)                  .464

   Sleep disorder                              5 (83.30)                    16 (59.30)                .379

   No regular exercise                         3 (50.00)                    15 (55.60)                \>.999

   No regular sex                              2 (33.30)                    7 (25.90)                 \>.999

   Number of comorbidities, mean (±*SD*)       5.33 (2.94)                  4.04 (2.17)               .224

  History of medicine (months), mean (±*SD*)                                                          

   Antibiotics                                 2.67 (1.72)                  4 (3.59)                  .387

   Anti-inflammatory                           8.33 (4.92)                  9.87 (9.77)               .173

   Alpha-blocker                               18.83 (23.60)                24.78 (47.72)             .77

  Laboratory data, mean (±*SD*)                                                                       

   Total testosterone (ng/dL)                  493.4 (173.99)               527.15 (172.39)           .668

   Prostate-specific antigen (ng/mL)           2.53 (2.57)                  1.38 (1.24)               .106

  Initial clinical severity, mean (±*SD*)                                                             

   NIH-CPSI                                                                                           

    Total score                                24.33 (7.45)                 28.85 (5.70)              .106

    Pain subscales                             11.83 (4.07)                 13.07 (2.99)              .395

    Urinary subscales                          4.33 (2.81)                  6.19 (2.22)               .087

    QoL subscales                              8.17 (3.43)                  9.59 (1.67)               .135

   VAS                                         5.00 (2.68)                  5.70 (1.35)               .350

   IPSS                                                                                               

    Total score                                11.67 (9.03)                 15.70 (8.74)              .316

    Irritative score                           6.00 (6.51)                  8.63 (6.04)               .348

    Obstructive score                          5.67 (2.88)                  7.07 (3.22)               .333

   IIEF-5                                      18.33 (4.13)                 17.33 (4.88)              .645

   EHS                                         3.17 (0.98)                  3.19 (0.92)               .965
  ---------------------------------------------------------------------------------------------------------------

*Note.* BMI = body mass index; CPPS = chronic pelvic pain syndrome; EHS = erection hardness score; IIEF-5: five-item version of the International Index of Erectile Function; IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shockwave therapy; NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index, QoL = quality of life; *SD* = standard deviation; VAS = visual analog scale.

Discussion {#section7-1557988317736585}
==========

All patients had undergone at least a 6-week trial of 3-As therapy, received adequate education by a urologist about the optimization of their 3-As use, and their clinical phenotypes of UPOINTS were reevaluated and corrected before enrolling in this study. Therefore, the current study population represented true nonresponders to 3-As therapy, which is a significant challenge to manage in clinical practice. In this study, 75.8% of patients with refractory CPPS who failed to respond to traditional 3-As therapy could achieve a clinical significant improvement after 4 weeks of LI-ESWT treatment; even more subjects (81.8%) were able to maintain the therapeutic efficacy at the 3-month follow-up. The current results are compatible with those of previous studies ([Table 4](#table4-1557988317736585){ref-type="table"}). In addition, none of the patients reported any adverse effect associated with LI-ESWT.

###### 

Literature Review of Studies About LI-ESWT in Patients With Chronic Pelvic Pain Syndrome.

![](10.1177_1557988317736585-table4)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Setup and protocol of LI-ESWT                                   Combined 3-As therapy   Outcomes                                                                                                                                                                                                                        
  ---------------------------- ------------------------------- ------------------------------- ----------------------- ----------------------------------------- ---------------------------------------- ------ ----- --- ---- ----- ----- ------------- ----------------------- -------------------------------------------------------------------- --------------------------------------------------------------------
  [@bibr43-1557988317736585]   Cohort study                    Minilith SL1                    14                      1, 4,12                                   0.11                                     2000   180   3   2    NA    No    No            −2.7(12wk)              −3.1(12wk)                                                           NA

  [@bibr43-1557988317736585]   Cohort study                    Duolith SD1                     20                      1, 4,12                                   0.25                                     3000   180   1   4    NA    No    No            −8.6(1wk)\              −2.4(1wk)\                                                           −4.1(1wk)\
                                                                                                                                                                                                                                                          −8.9(4wk)\              −2.8(4wk)\                                                           −3.8(4wk)\
                                                                                                                                                                                                                                                          −5.5(12wk)              −2.0(12wk)                                                           0 .0(12wk)

                                                                                                                                                                                                                                                                                                                                                       

  [@bibr44-1557988317736585]   RCT                             Duolith SD1                     30                      1, 4,12                                   0.25                                     3000   180   1   4    NA    No    No            −16.7(1wk)\             −33.3(1wk)\                                                          −15.6( 1wk)\
                                                                                                                                                                                                                                                          −16.7(4wk)\             −50(4wk)\                                                            −18.8(4wk)\
                                                                                                                                                                                                                                                          −16.7(12wk)             −50(12wk)                                                            −25 (12wk)

                                                                                                                                                                                                                                                                                                                                                       

  [@bibr40-1557988317736585]   RCT                             HB-ESWT-01                      8                       4,12                                      0.06\~MTD                                2000   120   5   2    Yes   No    No            CPSI↓≧6: 21.1% (4wk)\   NA                                                                   NA
                                                                                                                                                                                                                                                          23.7% (12wk)                                                                                 

                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                       

  [@bibr35-1557988317736585]   RCT                             Duolith SD1                     40                      1, 2, 3, 12 after first LI-ESWT session   0.25\~0.4\                               3000   180   1   4    NA    No    No            −5.1(1wk)\              −2.0(1wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^\    −1.0(1wk)^[b](#table-fn5-1557988317736585){ref-type="table-fn"}^\
                                                                                                                                                                 ( 0.05 mJ/mm2 was added in each week),                                                   −10.2(3wk)\             −5.1(3wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^\    −1.7(3wk)^[b](#table-fn5-1557988317736585){ref-type="table-fn"}^\
                                                                                                                                                                                                                                                          −7.1(12wk)              −4.3(12wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^    −0.9(12wk)\*

  [@bibr25-1557988317736585]   RCT                             Duolith SD1                     19                      16,20, 24                                 0.25                                     3000   180   1   4    NA    NA    NA            −4.47(16wk)\            −2.66 (16wk)\                                                        −0.71 (16wk)\
                                                                                                                                                                                                                                                          −1.06(20wk)\            −1.24 (20wk)\                                                        −0.39 (20wk)\
                                                                                                                                                                                                                                                          +0.38(24wk)             +0.53 (24wk)                                                         +0.12(24wk)

  [@bibr27-1557988317736585]   RCT                             KM-2000 S                       30                      12,24                                     0.25                                     3000   180   1   12   No    Yes   NA            −19.4(12wk)\            −9.3(12wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^\   −2.9(12wk)^[b](#table-fn5-1557988317736585){ref-type="table-fn"}^\
                                                                                                                                                                                                                                                          −17.4(24wk)             −9.2(24wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^    −3.2(24wk)^[a](#table-fn5-1557988317736585){ref-type="table-fn"}^

  [@bibr1-1557988317736585]    Cohort study                    E-S.W.T Roland, pagani, Italy   41                      2, 24, 48                                 0.25                                     2500   180   1   4    Yes   No    NA            −9.2(2wk)\              −4.1(2wk)\                                                           −5.9(2wk)\
                                                                                                                                                                                                                                                          −8.8(24wk)\             −3.5(24wk)\                                                          −6.6(24wk)\
                                                                                                                                                                                                                                                          −8.2(48wk)              −3.2(48wk)                                                           −6.6(48wk)

  Our study                    Cohort study                    Duolith SD1                     33                      1,4,12                                    0.25                                     3000   240   1   4    Yes   Yes   Dose taping   −9.06 (4wk)\            −2.38 (4wk)\                                                         −5.18 (4wk)\
                                                                                                                                                                                                                                                          −12.97 (12wk)\          −3.29 (12wk)                                                         −5.97 (12wk)
                                                                                                                                                                                                                                                          CPSI↓≧6: 75.8% (4wk)\                                                                        
                                                                                                                                                                                                                                                          81.8% (12wk)                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shock wave therapy; MTD = maximum tolerated dose; NA = not available; NIH-CPSI = National Institutes of Health-Chronic Prostatitis Symptom Index; RCT = randomized controlled trial; VAS = Visual Analogue Scale.

In NIH-CPSI pain domain. ^b^In NIH-CPSI urinary domain.

Because multiple physiological disorders account for major etiologies in most patients with CPPS, 3-As therapy, which covers several domains of UPOINTS, has been widely accepted as a first-line treatment for CPPS ([@bibr2-1557988317736585]; [@bibr7-1557988317736585]; [@bibr21-1557988317736585]; [@bibr34-1557988317736585]). However, up to 46% of patients with CPPS are still refractory to the adequate trial and maximum dosage of 3-As therapy in clinical practice, particularly among difficult-to-treat subpopulations (e.g., patients with prolonged symptoms and multifocal pain points; [@bibr34-1557988317736585]). Lifestyle modification, physiotherapy, trigger point massage, rectal massage, thermotherapy, reevaluating UPOINTS, switching to another type of 3-As medicine, and alternative medical approaches (such as phytotherapy, pentosan polysulfate, antidepressants, steroids, 5a-reductase inhibitors, anticholinergics, antispasmodics, and traditional Chinese medicine) are the common strategies adopted for nonresponders to 3-As therapy. Other invasive procedures, such as transcutaneous electrical nerve stimulation, electromagnetic treatment, acupuncture, balloon dilatation, laser coagulation, neuromodulation, intraprostatic injection, and even radical prostatectomy, were discussed ([@bibr4-1557988317736585]; [@bibr6-1557988317736585]; [@bibr12-1557988317736585]; [@bibr21-1557988317736585]; [@bibr24-1557988317736585]; [@bibr31-1557988317736585]). However, their efficacy is usually unsatisfactory and none of these procedures has entered clinical practice on a broader scale.

LI-ESWT, a noninvasive treatment that can reduce passive muscle tone, influence neuroplasticity and, most importantly, induce neovascularization and anti-inflammation, has become a novel, alternative treatment for CPPS ([@bibr11-1557988317736585]; [@bibr22-1557988317736585]; [@bibr23-1557988317736585]; [@bibr30-1557988317736585]). The hypothesis on the appropriate energy from LI-ESWT that could induce shear stress and intracellular microtrauma, and then stimulate endothelial nitric oxide synthase (eNOS) and release of vascular endothelial growth factors (VEGF) and proliferating cell nuclear antigen (PCNA), resulting in angiogenesis, has been proved in several animal studies ([@bibr38-1557988317736585]; [@bibr10-1557988317736585]; [@bibr33-1557988317736585]). Another possible mechanism through which LI-ESWT can improve CPPS may be mediated by anti-inflammatory action. Mariotto et al. reported that LI-ESWT could induce downregulation of NF-kB and NF-kB-dependent inflammatory genes, resulting in beneficial action on tissue inflammation ([@bibr23-1557988317736585]). LI-ESWT could also recruit endogenous mesenchymal stem cells to promote angiogenesis, tissue repair, and nerve generation in a rat model of pelvic neurovascular injuries ([@bibr16-1557988317736585]). Based on the gate control theory, LI-ESWT could stimulate high-frequent nerve impulses on the nociceptors, which then block the nerve impulse, by alleviating pain ([@bibr39-1557988317736585]). The dose--effect relationship in ESWT should be of concern ([@bibr42-1557988317736585]), and the optimal parameters of ESWT for CPPS are not yet determined.

Although LI-ESWT has been used in urology for treating Peyronie's disease and erectile dysfunction ([@bibr8-1557988317736585]), Zimmermann et al. first reported the experience of using LI-ESWT in the treatment of CPPS in 2008 ([@bibr43-1557988317736585]). In recent years, limited studies on LI-ESWT have reported positive results in the improvement of CPPS. The current study reviewed studies since 2008 in [Table 4](#table4-1557988317736585){ref-type="table"} ([@bibr1-1557988317736585]; [@bibr25-1557988317736585]; [@bibr27-1557988317736585]; [@bibr35-1557988317736585]; [@bibr40-1557988317736585]; [@bibr43-1557988317736585]; [@bibr44-1557988317736585]). Most of them had limited patient numbers or were not randomized controlled trials. The long-term effect of LI-ESWT is still equivocal ([@bibr1-1557988317736585]; [@bibr25-1557988317736585]), and only one study prior to the current study had evaluated the role of LI-ESWT in the treatment of patients with CPPS who were nonresponders to traditional 3-As therapy ([@bibr1-1557988317736585]). Because different generators and protocols of LI-ESWT were used in previous studies, the current results can only be compared with the other four studies that used the same device. Further studies are still needed to define an adequate therapeutic protocol, including location of the applied probe, energy density, and number of pulses and sessions, and to determine important predictors of successful response to LI-ESWT in patients with CPPS.

In the current study, most patients had concomitant alpha-blocker and anti-inflammatory drug use during and after LI-ESWT. After 12 weeks of LI-ESWT treatment, up to 72.7% of patients could taper 3-As medication and only 36.4% of patients still needed painkillers. The efficacy was maintained even better at the 3-month follow-up. The good efficacy of LI-ESWT in refractory CPPS may be because the therapy can cover the remaining domains of UPOINTS (such as organ specific, neurologic/systemic, tenderness, and even sexual dysfunction) to maximize the treatment effects. 3-As therapy only covers parts of UPOINTS, such as the domains of urinary and organ-specific function, infection, whereas LI-ESWT can play a part in other domains, thereby complementing the positive effect from a different prospective. In addition, no statistically significant difference in age, BMI, CPPS period and category, comorbidities, and personal habits was reported in the current study when responders were compared with nonresponders to LI-ESWT. Waist circumference was the only significant predictor identified for successful response to LI-ESWT in the current study. Patients who were nonresponders to LI-ESWT at the 3-month follow-up had a larger waist circumference (*p* = .022). In an in vitro study, the energy of LI-ESWT was reported to slowly decay or attenuate in fat tissue because it could not accumulate adequate energy in the target ([@bibr18-1557988317736585]). In contrast, Rogowski et al. reported that waist circumference appears to exert the most influence upon the presence and intensity of the inflammatory markers and micro-inflammatory response ([@bibr29-1557988317736585]). Thus, larger waist circumference, as the primary contributor of the inflammatory state and energy decay, might be a negative predictive factor for LI-ESWT in patients with CPPS.

The current study has several limitations. First, it was a single-arm prospective study, which lacks control or comparison to other types of therapy. Second, the patient number was limited; hence, comparison of the efficacy of LI-ESWT for different etiologies of CPPS is difficult. Third, the follow-up period was only 3 months; hence, the long-term efficacy of LI-ESWT could not be evaluated.

Conclusions {#section8-1557988317736585}
===========

LI-ESWT can serve as a salvage therapy in patients with CPPS who fail to respond to traditional 3-As therapy. At the 3-month follow-up, 81.8% of refractory patients with CPPS achieved a clinically significant improvement. Waist circumference was identified to be the only significant predictor of successful response to LI-ESWT. Further large and long-term studies are needed to compare the efficacy of different generators of LI-ESWT and to determine an adequate therapeutic protocol and important predictors in patients with different CPPS etiologies.
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